The Ministry of Health has published this Friday a new update of the vaccination strategy with the following priority groups that will follow the current ones and the immunization recommendations for people who have had the disease.
The document maintains age as the main risk factor and based on this it has added new groups to those agreed last week, such as 56 to 59 years, while leaving for later the definition of people with minor chronic diseases age 60 who will be immunized first.
Those who for the moment will not be subject to age are inmates: the prison population “will be vaccinated later depending on the availability of vaccines and regardless of age criteria.”
“For reasons of feasibility and access to the centers where they are located and, taking into account the greater risk of exposure and the principle of need and protection against vulnerability, it is recommended to group and simplify vaccination activities in this population, taking into account the circumstances of each center. The indicated vaccine will be used for each inmate depending on their individual circumstances (age), “he says.
The campaign will continue to run along a double track until new vaccines arrive: the one marked by messenger RNA drugs -Pfizer and Moderna-, which is reserved for the elderly, and that of AstraZeneca, based on an adenovirus-, and which for the moment It is dedicated to the population between 45 and 55 years of age and essential workers below that age.
In any case, the regimen must be administered with the same preparation because “data on interchangeability between vaccines are not available at the moment, although studies are under way.”
PFIZER AND MODERN
They are those that have been used in the first phase that began on December 27 with the first target groups of the 15 included in the strategy.
Comirnaty’s (Pfizer) regimen is two 0.3 ml doses 21 days apart, and Moderna’s is two 0.5 ml doses 28 days apart. Both will continue to be used to immunize the most vulnerable people due to their high age or risk factors related to a worse prognosis due to covid in this order:
– GROUP 1: Users of residences and their workers.
– GROUP 2: First-line health and social care.
– GROUP 3A: Workers who, even though they are not first-line, have a high level of exposure: workers in the hospital and primary care settings and in the fields of dentistry, dental hygiene and other health personnel who care for patients without a mask for more than 15 minutes.
– GROUP 5: Seniors.
5A: Over 80 years old.
5B: People from 70 to 79 years old.
5C: People from 60 to 69 years old
– Group 7: People under 60 years of age with high risk conditions for severe covid-19.
– GROUP 3B over 55 years: Personnel SP services management and response to the pandemic; health and social health personnel not previously vaccinated; physical therapists, occupational therapists, pharmacy offices, dental technicians; IIPP staff.
– GROUP 3C OVER 55 years: Rest of health and social health personnel not previously vaccinated.
– GROUP 6 OVER 55 YEARS OLD: Groups with an essential function for society
6A: Security Forces and Bodies, Emergencies and Armed Forces
6B: Early Childhood and Special Education Teachers and Staff
6C: Primary and Secondary Education Teachers and Staff
– GROUP 8: People aged 56-59 years
In groups 3A, 4, 5A, 7, 3B, 3C, 6A, 6B and 6C, vaccination “may overlap due to organizational and feasibility reasons.”
In this case, the regimen is two doses of 0.5 ml separated between 10 and 12 weeks (preferably 12), since a higher efficacy has been appreciated.
According to the strategy, and after reviewing in detail the safety information of this drug in people with one or more comorbidities, such as cardiovascular diseases, respiratory diseases or diabetes, who represented 39.3% of the total participants in clinical trials, it concludes that the safety profile is similar to that of the rest of the participants.
“Therefore, there are no safety concerns or contraindications for the use of this vaccine in people with concomitant diseases or treatments. Furthermore, the efficacy data of the vaccine are similar in participants without and with comorbidities,” the document states, that AstraZeneca reserves for these groups:
– GROUP 3B = 55 YEARS
– GROUP 3C = 55 YEARS OLD
– GROUP 4: Large dependents up to 55 years of age.
– GROUP 6 (6B, 6B AND 6C) = 55 YEARS OLD
– GROUP 9: People from 45 to 55 years old
Vaccination of groups 6B, 6C and 9 may overlap due to organizational and feasibility issues.
– GROUP 4: Large non-institutionalized dependents. This group will be immunized with messenger RNA vaccines or with AstraZeneca “depending on the age of the person and feasibility”.
This group includes those who have applied for recognition and those who have not done so yet but are “medically accredited for having illnesses that require intense support measures to develop their lives”, whether or not they are institutionalized.
People who are paid to care for them at home “will be vaccinated on the same visit” if they have not done so before.
AND WHO HAS PASSED THE COVID?
The vast majority of people infected with SARS-CoV-2 produce neutralizing antibodies, in addition to stimulating the induction of T-cell responses; the number of cases with documented reinfection is very low in the 6 months after diagnosis, but it is not yet clear in what percentage those who have passed the disease are protected and for how long.
Following these premises, the document divides the people who have been infected into four groups:
1. Over 55 years of age who have already received one dose: vaccination with a two-dose schedule.
2. Those over 55 years of age with a diagnosis of infection after receiving the first dose will receive the second when they are fully recovered and the isolation period has ended.
3. Under 55 years old. Single-dose vaccination six months after illness or diagnosis of infection.
4. Children under 55 years of age with a diagnosis of SARS-CoV-2 infection after receiving the first dose will complete the regimen at six months.